Skyline Therapeutics receives Orphan Drug Designation from FDA for SKG1108
The FDA granted Orphan Drug Designation to Skyline Therapeutics' SKG1108, a gene therapy for retinitis pigmentosa, aiming to restore visual function by generating new photo-sensing cells. The designation qualifies SKG1108 for incentives, accelerating its development and enhancing patient access.
Reference News
Skyline Therapeutics receives Orphan Drug Designation from FDA for SKG1108
The FDA granted Orphan Drug Designation to Skyline Therapeutics' SKG1108, a gene therapy for retinitis pigmentosa, aiming to restore visual function by generating new photo-sensing cells. The designation qualifies SKG1108 for incentives, accelerating its development and enhancing patient access.